Transaction · 0001804567-26-000018

Mottola Frank

Mottola Frank, SVP, CTOO, reported a transaction classified as other at SUPERNUS PHARMACEUTICALS, INC. involving 17000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

otherSEC transaction code JSVP, CTOO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Trade date
Nov 02, 2026
Filing date
Nov 04, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded17.0k$0.00 per share
Holdings after0Direct
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
ambiguous transaction codeThe transaction code is missing or represents other activity; review the filing and footnotes.

SUPN price since this filing

Daily closing prices, with the filing date and available return windows
SUPN · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +50.6%1w ago +44.8%1d ago +45.5%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
other
Code J
Identifier
0001804567-26-000018
Employee Stock Option (Right to Buy)
Transaction date
Nov 02, 2026
Filed Nov 04, 2026, 09:27 PM · 2d delay
Shares
17,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
0 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

SVP, Chief Tech. Ops. Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernu…

  2. F2

    Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernu…

  3. F3

    These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Sup…

  4. F4

    Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.

  5. F5

    On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.

  6. F6

    On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.

  7. F7

    On February 22, 2024, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on June 24, 2024.

  8. F8

    Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

  9. F9

    These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

  10. F10

    These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.

  11. F11

    These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.

  12. F12

    These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

  13. F13

    Option vests in four equal installments beginning February 22, 2020.

  14. F14

    The option vests in four equal annual installments beginning on February 21, 2021.

  15. F15

    The option vests in four equal annual installments beginning on February 19, 2022

  16. F16

    The option vests in four equal annual installments beginning on February 22, 2023.

  17. F17

    The option vests in four equal annual installments beginning on February 23, 2024.

  18. F18

    The option vests in four equal annual installments beginning on February 22, 2025.

  19. F19

    The option vests in four equal annual installments beginning on February 19, 2026.

  20. F20

    The option vests in four equal annual installments beginning on February 18, 2027.

Original filing · 0001804567-26-000018
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

SUPN